Virtus Investment Advisers, Inc. Allogene Therapeutics, Inc. Transaction History
Virtus Investment Advisers, Inc.
- $286 Million
- Q2 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 67,166 shares of ALLO stock, worth $86,644. This represents 0.03% of its overall portfolio holdings.
Number of Shares
67,166
Previous 81,270
17.35%
Holding current value
$86,644
Previous $118,000
36.44%
% of portfolio
0.03%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$24.1 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$21.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$14.4 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$14.3 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$13.5 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $186M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...